These results suggest that GTGKT peptide decreases the tumorigenic potential of cancer cells by decreasing the expression of cyclinD1, pGSK3βSer9 and inhibiting the binding of CAGE to GSK3β. This evidence concerns the gene GSK3B and cancer.